Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 15 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
Q2 2023 vs. Q1 2023
How the institutions holding Oruka Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 26 | 23 | −3 |
| Shares | 2.52M | 2.83M | +307.5K (+12.2%) |
| Value | $5.02M | $5.75M | +$730.4K (+14.6%) |
New holders (3)
Institutions that held Oruka Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Western Standard LLC | 630,191 | $1.28M | 1.11% |
| The PNC Financial Services Group, Inc. | 500 | $1.01K | 0.00% |
| Royal Bank of Canada | 258 | $1.00K | 0.00% |
Sold out (6)
Institutions that held Oruka Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Group One Trading, L.P. | 23,000 | $45.8K |
| Marquette Asset Management, LLC | 17,318 | $34.5K |
| HRT Financial LP | 14,408 | $28.0K |
| UBS Group AG | 1,787 | $3.56K |
| Morgan Stanley | 300 | $597 |
| Barclays PLC | 49 | $98 |